A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
暂无分享,去创建一个
[1] S. Martino,et al. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A Howell,et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Buzdar,et al. Fadrozole HCL (CGS‐16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials , 1996, Cancer.
[4] A. Howell,et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. , 1996, European journal of cancer.
[5] W. Miller. Aromatase inhibitors--where are we now? , 1996, British Journal of Cancer.
[6] J. V. Von Roenn,et al. Megestrol Acetate in Patients with AIDS-related Cachexia , 1994, Annals of Internal Medicine.
[7] P. Queirolo,et al. Second‐Line Hormonotherapy for Breast Cancer: Uselessness of First‐Line Continuation , 1993, American journal of clinical oncology.
[8] V. Gebski,et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Ebbs,et al. Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[10] J. Haybittle,et al. A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer. , 1992, British Journal of Cancer.
[11] S. Dahrouge,et al. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. , 1990, Seminars in oncology.
[12] J. de Haes,et al. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. , 1990, British Journal of Cancer.
[13] C. Spurr,et al. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Schaid,et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. , 1990, Journal of the National Cancer Institute.
[15] M. Williams,et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. , 1989, European journal of cancer & clinical oncology.
[16] A. Howell,et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. , 1988, European journal of cancer & clinical oncology.
[17] M. Peckham,et al. Chemotherapy of germ-cell ovarian tumours: first-line treatment with etoposide, bleomycin and cisplatin or carboplatin. , 1987, European journal of cancer & clinical oncology.
[18] D. Easton,et al. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. , 1987, Cancer research.
[19] D. Hayes,et al. New agents and new medical treatments for advanced breast cancer. , 1987, Seminars in oncology.
[20] J. Ingle,et al. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Morgan Lr. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. , 1985 .
[22] R. Santen,et al. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. , 1982, Cancer.
[23] J. Ingle,et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. , 1982, American journal of clinical oncology.
[24] H. Mouridsen,et al. Tamoxifen in advanced breast cancer. , 1978, Cancer treatment reviews.
[25] G. Kimmick,et al. Endocrine therapy in metastatic breast cancer. , 1998, Cancer treatment and research.
[26] R. Rubens,et al. Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.
[27] F. C. Barker,et al. On the Definition of the , 1949 .